Spero Therapeutics, Inc. (SPRO) stock
SPRONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 11/3041% below fair value
$1.00−0.02 (-1.96%)
Close on Nov 12, 2026Market cap $58.23MP/E –Yield –
Spero Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Spero Therapeutics's enterprise value was $8.54M on Nov 11, 2026, against $86.53M a year earlier. Over the last 5 years it ranged from -$97.98M to $392.43M, with a median of $10.86M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $8.54M | -89.7% |
| 2025 | Dec 31, 2025 | $82.59M | – |
| 2024 | Dec 31, 2024 | -$20.35M | – |
| 2023 | Dec 29, 2023 | -$15.92M | -167.2% |
| 2022 | Dec 30, 2022 | $23.70M | -94.0% |
| 2021 | Dec 31, 2021 | $392.43M | +4.3% |
| 2020 | Dec 31, 2020 | $376.32M | +337.9% |
| 2019 | Dec 31, 2019 | $85.94M | – |
| 2018 | Dec 31, 2018 | -$19.05M | – |
| 2017 | Dec 29, 2017 | -$21.07M | – |
See a number that looks wrong?